Repare Therapeutics Insider Liquidates 5.3 M Shares, Executives Sell All Holdings in Merger Wind‑Down <|end|>
Insider sales post‑Repare‑Xeno merger reveal confidence in the deal yet risk volatility; watch contingent value rights and oncology pipeline for future upside.
3 minutes to read